MicroRNAs: Pleiotropic players in congenital heart disease and regeneration

Journal of Thoracic Disease

Volumn 9, Issue , 2017, Pages S64-S81

  Hoelscher, Sarah C ^a   Doppler, Stefanie A ^a   Dreßen, Martina ^a   Lahm, Harald ^a   Lange, Rüdiger ^a,b   Krane, Markus ^a,b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

Cardiac regeneration; Congenital heart disease (CHD); MicroRNA (miR)

Indexed keywords

MICRORNA;

CONGENITAL HEART DISEASE; FALLOT TETRALOGY; HEART HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART VENTRICLE SEPTUM DEFECT; HOLT ORAM SYNDROME; HUMAN; HYPOPLASTIC LEFT HEART SYNDROME; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; REVIEW;

EID: 85016507215     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.21037/jtd.2017.03.149     Document Type: Review

References (132)

1. Zaffran S, Frasch M. Early signals in cardiac development. Circ Res 2002;91:457-69
2. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-97
3. Lee Y, Kim M, Han J, et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J 2004;23:4051-60
4. Bohnsack MT, Czaplinski K, Gorlich D. Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA 2004;10:185-91
5. Lee Y, Jeon K, Lee JT, et al. MicroRNA maturation: stepwise processing and subcellular localization. EMBO J 2002;21:4663-70
6. Khvorova A, Reynolds A, Jayasena SD. Functional siRNAs and miRNAs exhibit strand bias. Cell 2003;115:209-16
7. Kim VN, Han J, Siomi MC. Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol 2009;10:126-39
8. Ambros V. microRNAs: tiny regulators with great potential. Cell 2001;107:823-6
9. Winter J, Jung S, Keller S, et al. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol 2009;11:228-34
10. Chen XM. MicroRNA signatures in liver diseases. World J Gastroenterol 2009;15:1665-72
11. Krichevsky AM, King KS, Donahue CP, et al. A microRNA array reveals extensive regulation of microRNAs during brain development. RNA 2003;9:1274-81
12. Thum T, Galuppo P, Wolf C, et al. MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation 2007;116:258-67
13. Wong LL, Wang J, Liew OW, et al. MicroRNA and Heart Failure. Int J Mol Sci 2016;17:502
14. Gurha P. MicroRNAs in cardiovascular disease. Curr Opin Cardiol 2016;31:249-54
15. Bruneau BG. The developmental genetics of congenital heart disease. Nature 2008;451:943-8
16. Cordes KR, Srivastava D. MicroRNA regulation of cardiovascular development. Circ Res 2009;104:724-32
17. Liu N, Olson EN. MicroRNA regulatory networks in cardiovascular development. Dev Cell 2010;18:510-25
18. Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol 2002;39:1890-900
19. Olson EN, Schneider MD. Sizing up the heart: development redux in disease. Genes Dev 2003;17:1937-56
20. Albinsson S, Suarez Y, Skoura A, et al. MicroRNAs are necessary for vascular smooth muscle growth, differentiation, and function. Arterioscler Thromb Vasc Biol 2010;30:1118-26
21. Chen JF, Murchison EP, Tang R, et al. Targeted deletion of Dicer in the heart leads to dilated cardiomyopathy and heart failure. Proc Natl Acad Sci U S A 2008;105:2111-6
22. Boettger T, Braun T. A new level of complexity: the role of microRNAs in cardiovascular development. Circ Res 2012;110:1000-13
23. Chiavacci E, Dolfi L, Verduci L, et al. MicroRNA 218 mediates the effects of Tbx5a over-expression on zebrafish heart development. PLoS One 2012;7:e50536
24. Chiavacci E, D'Aurizio R, Guzzolino E, et al. MicroRNA 19a replacement partially rescues fin and cardiac defects in zebrafish model of Holt Oram syndrome. Sci Rep 2015;5:18240
25. D'Aurizio R, Russo F, Chiavacci E, et al. Discovering miRNA Regulatory Networks in Holt-Oram Syndrome Using a Zebrafish Model. Front Bioeng Biotechnol 2016;4:60
26. Fish JE, Wythe JD, Xiao T, et al. A Slit/miR-218/Robo regulatory loop is required during heart tube formation in zebrafish. Development 2011;138:1409-19
27. Bittel DC, Kibiryeva N, Marshall JA, et al. MicroRNA-421 Dysregulation is Associated with Tetralogy of Fallot. Cells 2014;3:713-23
28. Paul MH, Harvey RP, Wegner M, et al. Cardiac outflow tract development relies on the complex function of Sox4 and Sox11 in multiple cell types. Cell Mol Life Sci 2014;71:2931-45
29. Liang D, Xu X, Deng F, et al. miRNA-940 reduction contributes to human Tetralogy of Fallot development. J Cell Mol Med 2014;18:1830-9
30. Salameh A, Blanke K, Daehnert I. Role of connexins in human congenital heart disease: the chicken and egg problem. Front Pharmacol 2013;4:70
31. Wu Y, Ma XJ, Wang HJ, et al. Expression of Cx43-related microRNAs in patients with tetralogy of Fallot. World J Pediatr 2014;10:138-44
32. Anderson C, Catoe H, Werner R. MIR-206 regulates connexin43 expression during skeletal muscle development. Nucleic Acids Res 2006;34:5863-71
33. Zhang J, Chang JJ, Xu F, et al. MicroRNA deregulation in right ventricular outflow tract myocardium in nonsyndromic tetralogy of fallot. Can J Cardiol 2013;29:1695-703
34. Sucharov CC, Sucharov J, Karimpour-Fard A, et al. Micro-RNA expression in hypoplastic left heart syndrome. J Card Fail 2015;21:83-8
35. Callis TE, Pandya K, Seok HY, et al. MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J Clin Invest 2009;119:2772-86
36. Reddy S, Zhao M, Hu DQ, et al. Dynamic microRNA expression during the transition from right ventricular hypertrophy to failure. Physiol Genomics 2012;44:562-75
37. Lee DY, Deng Z, Wang CH, et al. MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression. Proc Natl Acad Sci U S A 2007;104:20350-5
38. Nagalingam RS, Sundaresan NR, Gupta MP, et al. A cardiac-enriched microRNA, miR-378, blocks cardiac hypertrophy by targeting Ras signaling. J Biol Chem 2013;288:11216-32
39. Holder AM, Klaassens M, Tibboel D, et al. Genetic factors in congenital diaphragmatic hernia. Am J Hum Genet 2007;80:825-45
40. Kuster DW, Mulders J, Ten Cate FJ, et al. MicroRNA transcriptome profiling in cardiac tissue of hypertrophic cardiomyopathy patients with MYBPC3 mutations. J Mol Cell Cardiol 2013;65:59-66
41. Zhao Y, Samal E, Srivastava D. Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature 2005;436:214-20
42. Srivastava D, Cserjesi P, Olson EN. A subclass of bHLH proteins required for cardiac morphogenesis. Science 1995;270:1995-9
43. Zhao Y, Ransom JF, Li A, et al. Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell 2007;129:303-17
44. Li J, Cao Y, Ma XJ, et al. Roles of miR-1-1 and miR-181c in ventricular septal defects. Int J Cardiol 2013;168:1441-6
45. Liu N, Bezprozvannaya S, Williams AH, et al. microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes Dev 2008;22:3242-54
46. Duisters RF, Tijsen AJ, Schroen B, et al. miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ Res 2009;104:170-8
47. Beppu H, Malhotra R, Beppu Y, et al. BMP type II receptor regulates positioning of outflow tract and remodeling of atrioventricular cushion during cardiogenesis. Dev Biol 2009;331:167-75
48. Ventura A, Young AG, Winslow MM, et al. Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell 2008;132:875-86
49. Wang J, Greene SB, Bonilla-Claudio M, et al. Bmp signaling regulates myocardial differentiation from cardiac progenitors through a MicroRNA-mediated mechanism. Dev Cell 2010;19:903-12
50. Porrello ER, Johnson BA, Aurora AB, et al. MiR-15 family regulates postnatal mitotic arrest of cardiomyocytes. Circ Res 2011;109:670-9
51. Li D, Ji L, Liu L, et al. Characterization of circulating microRNA expression in patients with a ventricular septal defect. PLoS One 2014;9:e106318
52. Kratsios P, Catela C, Salimova E, et al. Distinct roles for cell-autonomous Notch signaling in cardiomyocytes of the embryonic and adult heart. Circ Res 2010;106:559-72
53. Lu JR, McKinsey TA, Xu H, et al. FOG-2, a heart-and brain-enriched cofactor for GATA transcription factors. Mol Cell Biol 1999;19:4495-502
54. Vincentz JW, Barnes RM, Firulli AB. Hand factors as regulators of cardiac morphogenesis and implications for congenital heart defects. Birth Defects Res A Clin Mol Teratol 2011;91:485-94
55. Lichiardopol C, Militaru C, Popescu B, et al. Holt-Oram syndrome. Rom J Morphol Embryol 2007;48:67-70
56. Al-Qattan MM, Abou Al-Shaar H. Molecular basis of the clinical features of Holt-Oram syndrome resulting from missense and extended protein mutations of the TBX5 gene as well as TBX5 intragenic duplications. Gene 2015;560:129-36
57. Dreßen M, Lahm H, Lahm A, et al. A novel de novo TBX5 mutation in a patient with Holt-Oram syndrome leading to a dramatically reduced biological function. Mol Genet Genomic Med 2016;4:557-67
58. Bruneau BG, Nemer G, Schmitt JP, et al. A murine model of Holt-Oram syndrome defines roles of the T-box transcription factor Tbx5 in cardiogenesis and disease. Cell 2001;106:709-21
59. Yu X, Lin J, Zack DJ, et al. Analysis of regulatory network topology reveals functionally distinct classes of microRNAs. Nucleic Acids Res 2008;36:6494-503
60. Rothschild SC, Easley CA 4th, Francescatto L, et al. Tbx5-mediated expression of Ca(2+)/calmodulin-dependent protein kinase II is necessary for zebrafish cardiac and pectoral fin morphogenesis. Dev Biol 2009;330:175-84
61. Alajez NM, Lenarduzzi M, Ito E, et al. MiR-218 suppresses nasopharyngeal cancer progression through downregulation of survivin and the SLIT2-ROBO1 pathway. Cancer Res 2011;71:2381-91
62. Small EM, Sutherland LB, Rajagopalan KN, et al. MicroRNA-218 regulates vascular patterning by modulation of Slit-Robo signaling. Circ Res 2010;107:1336-44
63. Lahm H, Schon P, Doppler S, et al. Tetralogy of Fallot and Hypoplastic Left Heart Syndrome-Complex Clinical Phenotypes Meet Complex Genetic Networks. Curr Genomics 2015;16:141-58
64. O'Brien JE Jr, Kibiryeva N, Zhou XG, et al. Noncoding RNA expression in myocardium from infants with tetralogy of Fallot. Circ Cardiovasc Genet 2012;5:279-86
65. Schilham MW, Oosterwegel MA, Moerer P, et al. Defects in cardiac outflow tract formation and pro-B-lymphocyte expansion in mice lacking Sox-4. Nature 1996;380:711-4
66. Barth JL, Clark CD, Fresco VM, et al. Jarid2 is among a set of genes differentially regulated by Nkx2.5 during outflow tract morphogenesis. Dev Dyn 2010;239:2024-33
67. Valente M, Nascimento DS, Cumano A, et al. Sca-1+ cardiac progenitor cells and heart-making: a critical synopsis. Stem Cells Dev 2014;23:2263-73
68. Barron DJ, Kilby MD, Davies B, et al. Hypoplastic left heart syndrome. Lancet 2009;374:551-64
69. Smith T, Rajakaruna C, Caputo M, et al. MicroRNAs in congenital heart disease. Ann Transl Med 2015;3:333
70. Rao PK, Toyama Y, Chiang HR, et al. Loss of cardiac microRNA-mediated regulation leads to dilated cardiomyopathy and heart failure. Circ Res 2009;105:585-94
71. Chen JF, Mandel EM, Thomson JM, et al. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet 2006;38:228-33
72. Rindt H, Gulick J, Knotts S, et al. In vivo analysis of the murine beta-myosin heavy chain gene promoter. J Biol Chem 1993;268:5332-8
73. Beavers KR, Nelson CE, Duvall CL. MiRNA inhibition in tissue engineering and regenerative medicine. Adv Drug Deliv Rev 2015;88:123-37
74. Tay FC, Lim JK, Zhu H, et al. Using artificial microRNA sponges to achieve microRNA loss-of-function in cancer cells. Adv Drug Deliv Rev 2015;81:117-27
75. Ebert MS, Neilson JR, Sharp PA. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods 2007;4:721-6
76. Haraguchi T, Ozaki Y, Iba H. Vectors expressing efficient RNA decoys achieve the long-term suppression of specific microRNA activity in mammalian cells. Nucleic Acids Res 2009;37:e43
77. Sayed D, Rane S, Lypowy J, et al. MicroRNA-21 targets Sprouty2 and promotes cellular outgrowths. Mol Biol Cell 2008;19:3272-82
78. van Rooij E, Kauppinen S. Development of microRNA therapeutics is coming of age. EMBO Mol Med 2014;6:851-64
79. Chen PY, Weinmann L, Gaidatzis D, et al. Strand-specific 5'-O-methylation of siRNA duplexes controls guide strand selection and targeting specificity. RNA 2008;14:263-74
80. Chiu YL, Rana TM. siRNA function in RNAi: a chemical modification analysis. RNA 2003;9:1034-48
81. Ibrahim AF, Weirauch U, Thomas M, et al. MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res 2011;71:5214-24
82. Pramanik D, Campbell NR, Karikari C, et al. Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice. Mol Cancer Ther 2011;10:1470-80
83. Takeshita F, Patrawala L, Osaki M, et al. Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther 2010;18:181-7
84. Kota J, Chivukula RR, O'Donnell KA, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009;137:1005-17
85. Miyazaki Y, Adachi H, Katsuno M, et al. Viral delivery of miR-196a ameliorates the SBMA phenotype via the silencing of CELF2. Nat Med 2012;18:1136-41
86. Srivastava A. In vivo tissue-tropism of adeno-associated viral vectors. Curr Opin Virol 2016;21:75-80
87. Chen BD, He CH, Chen XC, et al. Targeting transgene to the heart and liver with AAV9 by different promoters. Clin Exp Pharmacol Physiol 2015;42:1108-17
88. Prasad KM, Smith RS, Xu Y, et al. A single direct injection into the left ventricular wall of an adeno-associated virus 9 (AAV9) vector expressing extracellular superoxide dismutase from the cardiac troponin-T promoter protects mice against myocardial infarction. J Gene Med 2011;13:333-41
89. Aalbers CJ, Tak PP, Vervoordeldonk MJ. Advancements in adeno-associated viral gene therapy approaches: exploring a new horizon. F1000 Med Rep 2011;3:17
90. Webb G, Mulder BJ, Aboulhosn J, et al. The care of adults with congenital heart disease across the globe: Current assessment and future perspective: A position statement from the International Society for Adult Congenital Heart Disease (ISACHD). Int J Cardiol 2015;195:326-33
91. Gatzoulis MA, Balaji S, Webber SA, et al. Risk factors for arrhythmia and sudden cardiac death late after repair of tetralogy of Fallot: a multicentre study. Lancet 2000;356:975-81
92. Iacobazzi D, Suleiman MS, Ghorbel M, et al. Cellular and molecular basis of RV hypertrophy in congenital heart disease. Heart 2016;102:12-7
93. Babu-Narayan SV, Kilner PJ, Li W, et al. Ventricular fibrosis suggested by cardiovascular magnetic resonance in adults with repaired tetralogy of fallot and its relationship to adverse markers of clinical outcome. Circulation 2006;113:405-13
94. Hu J, Sun P, Ruan X, et al. Mechanism of myocardial microvessel formation in cyanotic congenital heart disease. Circ J 2005;69:1089-93
95. Yin HL, Luo CW, Dai ZK, et al. Hypoxia-inducible factor-1alpha, vascular endothelial growth factor, inducible nitric oxide synthase, and endothelin-1 expression correlates with angiogenesis in congenital heart disease. Kaohsiung J Med Sci 2016;32:348-55
96. Chistiakov DA, Orekhov AN, Bobryshev YV. The role of cardiac fibroblasts in post-myocardial heart tissue repair. Exp Mol Pathol 2016;101:231-40
97. Rathod RH, Powell AJ, Geva T. Myocardial Fibrosis in Congenital Heart Disease. Circ J 2016;80:1300-7
98. Morkin E. Control of cardiac myosin heavy chain gene expression. Microsc Res Tech 2000;50:522-31
99. van Rooij E, Sutherland LB, Qi X, et al. Control of stressdependent cardiac growth and gene expression by a microRNA. Science 2007;316:575-9
100. Montgomery RL, Hullinger TG, Semus HM, et al. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation 2011;124:1537-47
101. Small EM, Frost RJ, Olson EN. MicroRNAs add a new dimension to cardiovascular disease. Circulation 2010;121:1022-32
102. Hullinger TG, Montgomery RL, Seto AG, et al. Inhibition of miR-15 protects against cardiac ischemic injury. Circ Res 2012;110:71-81
103. Sugimoto M, Kuwata S, Kurishima C, et al. Cardiac biomarkers in children with congenital heart disease. World J Pediatr 2015;11:309-15
104. Karakikes I, Chaanine AH, Kang S, et al. Therapeutic cardiac-targeted delivery of miR-1 reverses pressure overload-induced cardiac hypertrophy and attenuates pathological remodeling. J Am Heart Assoc 2013;2:e000078
105. Bernstein E, Kim SY, Carmell MA, et al. Dicer is essential for mouse development. Nat Genet 2003;35:215-7
106. Kuehbacher A, Urbich C, Zeiher AM, et al. Role of Dicer and Drosha for endothelial microRNA expression and angiogenesis. Circ Res 2007;101:59-68
107. Suárez Y, Fernández-Hernando C, Pober JS, et al. Dicer dependent microRNAs regulate gene expression and functions in human endothelial cells. Circ Res 2007;100:1164-73
108. Yang WJ, Yang DD, Na S, et al. Dicer is required for embryonic angiogenesis during mouse development. J Biol Chem 2005;280:9330-5
109. Suárez Y, Fernández-Hernando C, Yu J, et al. Dicerdependent endothelial microRNAs are necessary for postnatal angiogenesis. Proc Natl Acad Sci U S A 2008;105:14082-7
110. Corno AF, Milano G, Samaja M, et al. Chronic hypoxia: a model for cyanotic congenital heart defects. J Thorac Cardiovasc Surg 2002;124:105-12
111. Lemus-Varela ML, Flores-Soto ME, Cervantes-Munguia R, et al. Expression of HIF-1 alpha, VEGF and EPO in peripheral blood from patients with two cardiac abnormalities associated with hypoxia. Clin Biochem 2010;43:234-9
112. Fasanaro P, D'Alessandra Y, Di Stefano V, et al. MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. J Biol Chem 2008;283:15878-83
113. Hua Z, Lv Q, Ye W, et al. MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. PLoS One 2006;1:e116
114. Kulshreshtha R, Ferracin M, Wojcik SE, et al. A microRNA signature of hypoxia. Mol Cell Biol 2007;27:1859-67
115. Himeno W. Angiogenic growth factors in patients with cyanotic congenital heart disease and in normal children. Kurume Med J 2001;48:111-6
116. Ylä-Herttuala S, Alitalo K. Gene transfer as a tool to induce therapeutic vascular growth. Nat Med 2003;9:694-701
117. Zhang J, Ko JM, Guileyardo JM, et al. A review of spontaneous closure of ventricular septal defect. Proc (Bayl Univ Med Cent) 2015;28:516-20
118. Fuziwara CS, Kimura ET. Insights into Regulation of the miR-17-92 Cluster of miRNAs in Cancer. Front Med (Lausanne) 2015;2:64
119. Jin HY, Oda H, Lai M, et al. MicroRNA-17~92 plays a causative role in lymphomagenesis by coordinating multiple oncogenic pathways. EMBO J 2013;32:2377-91
120. Dews M, Homayouni A, Yu D, et al. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet 2006;38:1060-5
121. Arnold RR, Loukanov T, Gorenflo M. Hypoplastic left heart syndrome-unresolved issues. Front Pediatr 2014;2:125
122. Pola R, Ling LE, Silver M, et al. The morphogen Sonic hedgehog is an indirect angiogenic agent upregulating two families of angiogenic growth factors. Nat Med 2001;7:706-11
123. Pourrajab F, Vakili Zarch A, Hekmatimoghaddam S, et al. MicroRNAs; easy and potent targets in optimizing therapeutic methods in reparative angiogenesis. J Cell Mol Med 2015;19:2702-14
124. Knowles RL, Bull C, Wren C, et al. Mortality with congenital heart defects in England and Wales, 1959-2009: exploring technological change through period and birth cohort analysis. Arch Dis Child 2012;97:861-5
125. Da Costa Martins PA, De Windt LJ. MicroRNAs in control of cardiac hypertrophy. Cardiovasc Res 2012;93:563-72
126. Wang J, Liew OW, Richards AM, et al. Overview of MicroRNAs in Cardiac Hypertrophy, Fibrosis, and Apoptosis. Int J Mol Sci 2016;17(5)
127. van Rooij E, Sutherland LB, Liu N, et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci U S A 2006;103:18255-60
128. Naeije R, Manes A. The right ventricle in pulmonary arterial hypertension. Eur Respir Rev 2014;23:476-87
129. Hua Y, Zhang Y, Ren J. IGF-1 deficiency resists cardiac hypertrophy and myocardial contractile dysfunction: role of microRNA-1 and microRNA-133a. J Cell Mol Med 2012;16:83-95
130. Li Q, Song XW, Zou J, et al. Attenuation of microRNA-1 derepresses the cytoskeleton regulatory protein twinfilin-1 to provoke cardiac hypertrophy. J Cell Sci 2010;123:2444-52
131. Sayed D, Hong C, Chen IY, et al. MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ Res 2007;100:416-24
132. Chery J, Wong J, Huang S, et al. Regenerative Medicine Strategies for Hypoplastic Left Heart Syndrome. Tissue Eng Part B Rev 2016;22:459-69